Bacterial surface appendages as targets for novel antibacterial therapeutics

Future Microbiology

Volumn 9, Issue 7, 2014, Pages 887-900

  Steadman, David ^a   Lo, Alvin ^b   Waksman, Gabriel ^a   Remaut, Han ^b,c  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^c VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

antibacterial; antibiotic; antibiotic resistance; antivirulence; curli; pili; pilicides

Indexed keywords

ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; CURLI PROTEIN; CURLICIDE DERIVATIVE; PILICIDE DERIVATIVE; PILUS POLYMERIZATION INHIBITOR; RECEPTOR; SMALL MOLECULE TRANSPORT AGENT; UNCLASSIFIED DRUG; VIRULENCE FACTOR;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BACTERIAL MEMBRANE; BACTERIAL SURFACE APPENDAGE; BACTERIAL VIRULENCE; BIOGENESIS; CHAPERONE USHER PILI; DRUG TARGETING; EXTRACELLULAR MATRIX; GRAM NEGATIVE BACTERIUM; HUMAN; MULTIDRUG RESISTANCE; NONHUMAN; POLYMERIZATION; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TYPE III SECRETION SYSTEM; TYPE IV SECRETION SYSTEM; ANIMAL; CELL SURFACE; DRUG EFFECTS; GENETICS; GRAM-NEGATIVE BACTERIAL INFECTIONS; METABOLISM; MICROBIOLOGY; VIRULENCE;

ANIMALS; ANTI-BACTERIAL AGENTS; CELL SURFACE EXTENSIONS; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; VIRULENCE;

EID: 84906675574     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.14.46     Document Type: Review

References (108)

1. Thanassi DG, Bliska JB, Christie PJ. Surface organelles assembled by secretion systems of Gram-negative bacteria: diversity in structure and function. Fems Microbiol. Rev. 36(6), 1046-1082 (2012).
2. Lo AWH, Moonens K, Remaut H. Chemical attenuation of pilus function and assembly in Gram-negative bacteria. Curr. Opin. Microbiol. 16(1), 85-92 (2013).
3. Stamm WE, Norrby SR. Urinary tract infections: disease panorama and challenges. J. Infect. Dis. 183(Suppl. 1), S1-S4 (2001).
4. Barnhart MM, Chapman MR. Curli biogenesis and function. Ann. Rev. Microbiol. 60(1), 131-147 (2006).
5. Marshall NC, Finlay BB. Targeting the type III secretion system to treat bacterial infections. Expert Opin. Ther. Targets 18(2), 137-152 (2014).
6. Smith MA, Coincon M, Paschos A et al. Identification of the binding site of Brucella VirB8 interaction inhibitors. Chem. Biol. 19(8), 1041-1048 (2012).
7. Clatworthy AE, Pierson E, Hung DT. Targeting virulence: a new paradigm for antimicrobial therapy. Nat. Chem. Biol. 3(9), 541-548 (2007).
8. Fernebro J. Fighting bacterial infections - future treatment options. Drug Resist. Updat. 14(2), 125-139 (2011).
9. Allen WJ, Phan G, Waksman G. Pilus biogenesis at the outer membrane of Gram-negative bacterial pathogens. Curr. Opin. Struct. Biol. 22(4), 500-506 (2012).
10. Busch A, Waksman G. Chaperone-usher pathways: diversity and pilus assembly mechanism. Philos. Trans. R Soc. Lond. B Biol. Sci. 367(1592), 1112-1122 (2012).
11. Geibel S, Waksman G. The molecular dissection of the chaperone-usher pathway. Biochim. Biophys. Acta 1843(8), 1559-1567 (2014).
12. Waksman G, Hultgren SJ. Structural biology of the chaperone-usher pathway of pilus biogenesis. Nat. Rev. Microbiol. 7(11), 765-774 (2009).
13. Anderson GG, Palermo JJ, Schilling JD, Roth R, Heuser J, Hultgren SJ. Intracellular bacterial biofilm-like pods in urinary tract infections. Science 301(5629), 105-107 (2003).
14. Mulvey MA, Lopez-Boado YS, Wilson CL et al. Induction and evasion of host defenses by Type 1-piliated uropathogenic Escherichia coli. Science 282(5393), 1494-1497 (1998).
15. Roberts JA, Marklund BI, Ilver D et al. The Gal(alpha 1-4)Gal-specific tip adhesin of Escherichia coli P-fimbriae is needed for pyelonephritis to occur in the normal urinary tract. Proc. Natl Acad. Sci. USA 91(25), 11889-11893 (1994).
16. Nishiyama M, Ishikawa T, Rechsteiner H, Glockshuber R. Reconstitution of pilus assembly reveals a bacterial outer membrane catalyst. Science 320(5874), 376-379 (2008).
17. Jones CH, Pinkner JS, Nicholes AV, Slonim LN, Abraham SN, Hultgren SJ. FimC is a periplasmic PapD-like chaperone that directs assembly of type 1 pili in bacteria. Proc. Natl Acad. Sci. USA 90(18), 8397-8401 (1993).
18. Geibel S, Procko E, Hultgren SJ, Baker D, Waksman G. Structural and energetic basis of folded-protein transport by the FimD usher. Nature 496(7444), 243-246 (2013).
19. Sauer FG, Fütterer K, Pinkner JS, Dodson KW, Hultgren SJ, Waksman G. Structural basis of chaperone function and pilus biogenesis. Science 285(5430), 1058-1061 (1999).
20. Kuehn MJ, Heuser J, Normark S, Hultgren SJ. P pili in uropathogenic E. coli are composite fibres with distinct fibrillar adhesive tips. Nature 356(6366), 252-255 (1992).
21. Lee YM, Dodson KW, Hultgren SJ. Adaptor function of PapF depends on donor strand exchange in p-pilus biogenesis of Escherichia coli. J. Bacteriol. 189(14), 5276-5283 (2007).
22. Båga M, Norgren M, Normark S. Biogenesis of E. coli Pap pili: PapH, a minor pilin subunit involved in cell anchoring and length modulation. Cell 49(2), 241-251 (1987).
23. Jones CH, Pinkner JS, Roth R et al. FimH adhesin of type 1 pili is assembled into a fibrillar tip structure in the Enterobacteriaceae. Proc. Natl Acad. Sci. USA 92(6), 2081-2085 (1995).
24. Hahn E, Wild P, Hermanns U et al. Exploring the 3D molecular architecture of Escherichia coli type 1 pili. J. Mol. Biol. 323(5), 845-857 (2002).
25. Vetsch M, Puorger C, Spirig T, Grauschopf U, Weber-Ban EU, Glockshuber R. Pilus chaperones represent a new type of protein-folding catalyst. Nature 431(7006), 329-333 (2004).
26. Bann JG, Pinkner JS, Frieden C, Hultgren SJ. Catalysis of protein folding by chaperones in pathogenic bacteria. Proc. Natl Acad. Sci. USA 101(50), 17389-17393 (2004).
27. Choudhury D, Thompson A, Stojanoff V et al. X-ray structure of the FimC-FimH chaperone-adhesin complex from uropathogenic Escherichia coli. Science 285(5430), 1061-1066 (1999).
28. Barnhart MM, Sauer FG, Pinkner JS, Hultgren SJ. Chaperone-subunit-usher interactions required for donor strand exchange during bacterial pilus assembly. J. Bacteriol. 185(9), 2723-2730 (2003).
29. Remaut H, Rose RJ, Hannan TJ et al. Donor-strand exchange in chaperone-assisted pilus assembly proceeds through a concerted' strand displacement mechanism. Mol. Cell 22(6), 831-842 (2006).
30. Sauer FG, Pinkner JS, Waksman G, Hultgren SJ. Chaperone priming of pilus subunits facilitates a topological transition that drives fiber formation. Cell 111(4), 543-551 (2002).
31. Vetsch M, Erilov D, Moliere N, Nishiyama M, Ignatov O, Glockshuber R. Mechanism of fibre assembly through the chaperone-usher pathway. EMBO Rep. 7(7), 734-738 (2006).
32. Verger D, Miller E, Remaut H, Waksman G, Hultgren S. Molecular mechanism of P pilus termination in uropathogenic Escherichia coli. EMBO Rep. 7(12), 1228-1232 (2006).
33. Bouckaert J, Berglund J, Schembri M et al. Receptor binding studies disclose a novel class of high-affinity inhibitors of the Escherichia coli FimH adhesin. Mol. Microbiol. 55(2), 441-455 (2005).
34. Hung C-S, Bouckaert J, Hung D et al. Structural basis of tropism of Escherichia coli to the bladder during urinary tract infection. Mol. Microbiol. 44(4), 903-915 (2002).
35. Wellens A, Garofalo C, Nguyen H et al. Intervening with urinary tract infections using anti-adhesives based on the crystal structure of the FimH-oligomannose-3 complex. PLoS ONE 3(4), (2008).
36. Jiang X, Abgottspon D, Kleeb S et al. Antiadhesion therapy for urinary tract infections - a balanced PK/PD profile proved to be key for success. J. Med. Chem. 55(10), 4700-4713 (2012).
37. Klein T, Abgottspon D, Wittwer M et al. FimH antagonists for the oral treatment of urinary tract infections: from design and synthesis to in vitro and in vivo evaluation. J. Med. Chem. 53(24), 8627-8641 (2010).
38. Schwardt O, Rabbani S, Hartmann M et al. Design, synthesis and biological evaluation of mannosyl triazoles as FimH antagonists. Biorg. Med. Chem. 19(21), 6454-6473 (2011).
39. Wellens A, Lahmann M, Touaibia M et al. The tyrosine gate as a potential entropic lever in the receptor-binding site of the bacterial adhesin FimH. Biochemistry 51(24), 4790-4799 (2012).
40. Han Z, Pinkner JS, Ford B et al. Structure-based drug design and optimization of mannoside bacterial FimH antagonists. J. Med. Chem. 53(12), 4779-4792 (2010).
41. Cusumano CK, Pinkner JS, Han Z et al. Treatment and prevention of urinary tract infection with orally active fimh inhibitors. Sci. Trans. Med. 3(109), (2011).
42. Guiton PS, Cusumano CK, Kline KA et al. Combinatorial small-molecule therapy prevents uropathogenic Escherichia coli catheter-associated urinary tract infections in mice. Antimicrob. Agents Chemother. 56(9), 4738-4745 (2012).
43. Totsika M, Kostakioti M, Hannan TJ et al. A FimH inhibitor prevents acute bladder infection and treats chronic cystitis caused by multidrug-resistant uropathogenic Escherichia coli ST131. J. Infect. Dis. 208(6), 921-928 (2013).
44. Hannan TJ, Totsika M, Mansfield KJ, Moore KH, Schembri MA, Hultgren SJ. Host-pathogen checkpoints and population bottlenecks in persistent and intracellular uropathogenic Escherichia coli bladder infection. Fems Microbiol. Rev. 36(3), 616-648 (2012).
45. Krachler AM, Orth K. Targeting the bacteria-host interface: strategies in anti-adhesion therapy. Virulence 4(4), 284-294 (2013).
46. Zav'yalov V, Zavialov A, Zav'yalova G, Korpela T. Adhesive organelles of Gram-negative pathogens assembled with the classical chaperone/usher machinery: structure and function from a clinical standpoint. Fems Microbiol. Rev. 34(3), 317-378 (2010).
47. Brument S, Sivignon A, Dumych TI et al. Thiazolylaminomannosides as potent antiadhesives of type 1 piliated Escherichia coli isolated from Crohn's disease patients. J. Med. Chem. 56(13), 5395-5406 (2013).
48. Larsson A, Ohlsson J, Dodson KW, Hultgren SJ, Nilsson U, Kihlberg J. Quantitative studies of the binding of the class II PapG adhesin from uropathogenic Escherichia coli to oligosaccharides. Biorg. Med. Chem. 11(10), 2255-2261 (2003).
49. Ohlsson J, Jass J, Uhlin BE, Kihlberg J, Nilsson UJ. Discovery of potent inhibitors of PapG adhesins from uropathogenic Escherichia coli through synthesis and evaluation of galabiose derivatives. Chembiochem 3(8), 772-779 (2002).
50. Salminen A, Loimaranta V, Joosten JaF. Inhibition of P-fimbriated Escherichia coli adhesion by multivalent galabiose derivatives studied by a live-bacteria application of surface plasmon resonance. J. Antimicrob. Chemother. 60(3), 495-501 (2007).
51. Saulino ET, Bullitt E, Hultgren SJ. Snapshots of usher-mediated protein secretion and ordered pilus assembly. Proc. Natl Acad. Sci. USA 97(16), 9240-9245 (2000).
52. Lo AWH, Van De Water K, Gane PJ et al. Suppression of type 1 pilus assembly in uropathogenic Escherichia coli by chemical inhibition of subunit polymerization. J. Antimicrob. Chemother. 69(4), 1017-1026 (2013).
53. Svensson A, Larsson A, Emtenäs H. Design and evaluation of pilicides: potential novel antibacterial agents directed against uropathogenic Escherichia coli. Chembiochem 2(12), 915-918 (2001).
54. Hung DL, Knight SD, Woods RM, Pinkner JS, Hultgren SJ. Molecular basis of two subfamilies of immunoglobulin-like chaperones. EMBO J. 15(15), 3792-3805 (1996).
55. Emtenäs H, Åhlin K, Pinkner JS, Hultgren SJ, Almqvist F. Design and parallel solid-phase synthesis of ring-fused 2-pyridinones that target pilus biogenesis in pathogenic bacteria. J. Comb. Chem. 4(6), 630-639 (2002).
56. Emtenas H, Carlsson M, Pinkner JS, Hultgren SJ, Almqvist F. Stereoselective synthesis of optically active bicyclic [small beta]-lactam carboxylic acids that target pilus biogenesis in pathogenic bacteria. Org. Biomol. Chem. 1(8), 1308-1314 (2003).
57. Tengel T, Fex T, Emtenas H, Almqvist F, Sethson I, Kihlberg J. Use of F-19 NMR spectroscopy to screen chemical libraries for ligands that bind to proteins. Org. Biomol. Chem. 2(5), 725-731 (2004).
58. Aberg V, Hedenstrom M, Pinkner JS, Hultgren SJ, Almqvist F. C-terminal properties are important for ring-fused 2-pyridones that interfere with the chaperone function in uropathogenic E. coli. Org. Biomol. Chem. 3(21), 3886-3892 (2005).
59. Aberg V, Sellstedt M, Hedenstrom M, Pinkner JS, Hultgren SJ, Almqvist F. Design, synthesis and evaluation of peptidomimetics based on substituted bicyclic 2-pyridones - targeting virulence of uropathogenic E. coli. Biorg. Med. Chem. 14(22), 7563-7581 (2006).
60. Pinkner JS, Remaut H, Buelens F et al. Rationally designed small compounds inhibit pilus biogenesis in uropathogenic bacteria. Proc. Natl Acad. Sci. USA 103(47), 17897-17902 (2006).
61. Chorell E, Pinkner JS, Phan G et al. Design and synthesis of C-2 substituted thiazolo and dihydrothiazolo ring-fused 2-pyridones: pilicides with increased antivirulence activity. J. Med. Chem. 53(15), 5690-5695 (2010).
62. Chorell E, Bengtsson C, Banchelin TS-L. Synthesis and application of a bromomethyl substituted scaffold to be used for efficient optimization of anti-virulence activity. Eur. J. Med. Chem. 46(4), 1103-1116 (2011).
63. Chorell E, Pinkner JS, Bengtsson C et al. Mapping pilicide anti-virulence effect in Escherichia coli, a comprehensive structure-activity study. Biorg. Med. Chem. 20(9), 3128-3142 (2012).
64. Chorell E, Pinkner JS, Bengtsson C et al. Design and synthesis of fluorescent pilicides and curlicides: bioactive tools to study bacterial virulence mechanisms. Chem. Eur. J. 18(15), 4522-4532 (2012).
65. Blanco LP, Evans ML, Smith DR, Badtke MP, Chapman MR. Diversity, biogenesis and function of microbial amyloids. Trends Microbiol. 20(2), 66-73 (2012).
66. Hammer ND, Mcguffie BA, Zhou Y et al. The C-terminal repeating units of CsgB direct bacterial functional amyloid nucleation. J Mol. Biol. 422(3), 376-389 (2012).
67. Nenninger AA, Robinson LS, Hammer ND et al. CsgE is a curli secretion specificity factor that prevents amyloid fibre aggregation. Mol. Microbiol. 81(2), 486-499 (2011).
68. Nenninger AA, Robinson LS, Hultgren SJ. Localized and efficient curli nucleation requires the chaperone-like amyloid assembly protein CsgF. Proc. Natl Acad. Sci. USA 106(3), 900-905 (2009).
69. Kuner P, Bohrmann B, Tjernberg LO et al. Controlling polymerization of β-amyloid and prion-derived peptides with synthetic small molecule ligands. J. Biol. Chem. 275(3), 1673-1678 (2000).
70. Andersson EK, Bengtsson C, Evans ML et al. Modulation of curli assembly and pellicle biofilm formation by chemical and protein chaperones. Chem. Biol. 20(10), 1245-1254 (2013).
71. Thorsett ED, Latimer LH. Therapeutic approaches to Alzheimer's disease. Curr. Opin. Chem. Biol. 4(4), 377-382 (2000).
72. Aberg V, Norman F, Chorell E et al. Microwave-assisted decarboxylation of bicyclic 2-pyridone scaffolds and identification of A[small beta]-peptide aggregation inhibitors. Org. Biomol. Chem. 3(15), 2817-2823 (2005).
73. Cegelski L, Pinkner JS, Hammer ND et al. Small-molecule inhibitors target Escherichia coli amyloid biogenesis and biofilm formation. Nat. Chem. Biol. 5(12), 913-919 (2009).
74. Worrall LJ, Lameignere E, Strynadka NCJ. Structural overview of the bacterial injectisome. Curr. Opin. Microbiol. 14(1), 3-8 (2011).
75. Izore T, Job V, Dessen A. Biogenesis, regulation, and targeting of the Type III secretion system. Structure 19(5), 603-612 (2011).
76. Neyt C, Cornelis GR. Role of SycD, the chaperone of the Yersinia Yop translocators YopB and YopD. Mol. Microbiol. 31(1), 143-156 (1999).
77. Cornelis GR. The Type III secretion injectisome. Nat. Rev. Micro. 4(11), 811-825 (2006).
78. Tsou LK, Dossa PD, Hang HC. Small molecules aimed at Type III secretion systems to inhibit bacterial virulence. Medchemcomm 4(1), 68-79 (2013).
79. Duncan MC, Linington RG, Auerbuch V. Chemical inhibitors of the type three secretion system: disarming bacterial pathogens. Antimicrob. Agents Chemother 56(11), 5433-5441 (2012).
80. Aiello D, Williams JD, Majgier-Baranowska H et al. Discovery and characterization of inhibitors of Pseudomonas aeruginosa type III secretion. Antimicrob. Agents Chemother. 54(5), 1988-1999 (2010).
81. Kim OK, Garrity-Ryan LK, Bartlett VJ et al. N-hydroxybenzimidazole inhibitors of the transcription factor LcrF in yersinia: novel antivirulence agents. J. Med. Chem. 52(18), 5626-5634 (2009).
82. Tree JJ, Wang D, Mcinally C et al. Characterization of the effects of salicylidene acylhydrazide compounds on type III secretion in Escherichia coli O157:H7. Infect. Immun. 77(10), 4209-4220 (2009).
83. Gong S, Lei L, Chang X, Belland R, Zhong G. Chlamydia trachomatis secretion of hypothetical protein CT622 into host cell cytoplasm via a secretion pathway that can be inhibited by the type III secretion system inhibitor compound 1. Microbiology 157(4), 1134-1144 (2011).
84. Muschiol S, Bailey L, Gylfe A. A small-molecule inhibitor of type III secretion inhibits different stages of the infectious cycle of Chlamydia trachomatis. Proc. Natl Acad. Sci. USA 103(39), 14566-14571 (2006).
85. Negrea A, Bjur E, Ygberg SE, Elofsson M, Wolf-Watz H, Rhen M. Salicylidene acylhydrazides that affect type III protein secretion in Salmonella enterica serovar Typhimurium. Antimicrob. Agents Chemother. 51(8), 2867-2876 (2007).
86. Veenendaal AKJ, Sundin C, Blocker AJ. Small-molecule Type III secretion system inhibitors block assembly of the Shigella Type III secretion. J. Bacteriol. 191(2), 563-570 (2009).
87. Felise HB, Nguyen HV, Pfuetzner RA et al. An inhibitor of Gram-negative bacterial virulence protein secretion. Cell Host Microbe 4(4), 325-336 (2008).
88. Kline T, Felise HB, Barry KC, Jackson SR, Nguyen HV, Miller SI. Substituted 2-imino-5-arylidenethiazolidin-4-one inhibitors of bacterial Tpe III secretion. J. Med. Chem. 51(22), 7065-7074 (2008).
89. Kline T, Barry KC, Jackson SR, Felise HB, Nguyen HV, Miller SI. Tethered thiazolidinone dimers as inhibitors of the bacterial Type III secretion system. Bioorg. Med. Chem. Lett. 19(5), 1340-1343 (2009).
90. Harmon DE, Davis AJ, Castillo C, Mecsas J. Identification and characterization of small-molecule inhibitors of yop translocation in Yersinia pseudotuberculosis. Antimicrob. Agents Chemother. 54(8), 3241-3254 (2010).
91. Pan NJ, Brady MJ, Leong JM, Goguen JD. Targeting Type III secretion in Yersinia pestis. Antimicrob. Agents Chemother. 53(2), 385-392 (2009).
92. Linington RG, Robertson M, Gauthier A et al. Caminosides BD, antimicrobial glycolipids isolated from the marine sponge Caminus sphaeroconia. J. Nat. Prod. 69(2), 173-177 (2006).
93. Kimura K, Iwatsuki M, Nagai T et al. A small-molecule inhibitor of the bacterial type III secretion system protects against in vivo infection with Citrobacter rodentium. J. Antibiot. 64(2), 197-203 (2011).
94. Iwatsuki M, Uchida R, Yoshijima H et al. Guadinomines, Type III secretion system inhibitors, produced by Streptomyces sp. K01-0509. J. Antibiot. 61(4), 222-229 (2008).
95. Swietnicki W, Carmany D, Retford M et al. Identification of small-molecule inhibitors of Yersinia pestis type III secretion system YscN ATPase. PLoS ONE 6(5), e19716 (2011).
96. Thomas CM, Nielsen KM. Mechanisms of, and barriers to, horizontal gene transfer between bacteria. Nat. Rev. Micro. 3(9), 711-721 (2005).
97. Backert S, Selbach M. Role of type IV secretion in Helicobacter pylori pathogenesis. Cell. Microbiol. 10(8), 1573-1581 (2008).
98. Cao TB, Saier MH. Conjugal type IV macromolecular transfer systems of Gram-negative bacteria: organismal distribution, structural constraints and evolutionary conclusions. Microbiology 147(12), 3201-3214 (2001).
99. Fronzes R, Schäfer E, Wang L, Saibil HR, Orlova EV, Waksman G. Structure of a type IV secretion system core complex. Science 323(5911), 266-268 (2009).
100. Chandran V, Fronzes R, Duquerroy S, Cronin N, Navaza J, Waksman G. Structure of the outer membrane complex of a type IV secretion system. Nature 462(7276), 1011-1015 (2009).
101. LowHH, Gubellini F, Rivera-Calzada A et al. Structure of a type IV secretion system. Nature 508(7497), 550-553 (2014).
102. Atmakuri K, Cascales E, Christie PJ. Energetic components VirD4, VirB11 and VirB4 mediate early DNA transfer reactions required for bacterial type IV secretion. Mol. Microbiol. 54(5), 1199-1211 (2004).
103. Aly KA, Baron C. The VirB5 protein localizes to the T-pilus tips in Agrobacterium tumefaciens. Microbiology 153(11), 3766-3775 (2007).
104. Mossey P, Hudacek A, Das A. Agrobacterium tumefaciens type IV secretion protein VirB3 is an inner membrane protein and requires VirB4, VirB7, and VirB8 for stabilization. J. Bacteriol. 192(11), 2830-2838 (2010).
105. Paschos A, Patey G, Sivanesan D et al. Dimerization and interactions of Brucella suis VirB8 with VirB4 and VirB10 are required for its biological activity. Proc. Natl Acad. Sci. USA 103(19), 7252-7257 (2006).
106. Paschos A, Den Hartigh A, Smith MA et al. An in vivo high-throughput screening approach targeting the type IV secretion system component VirB8 identified inhibitors of Brucella abortus 2308 proliferation. Infect. Immun. 79(3), 1033-1043 (2011).
107. Arts IS, Ball G, Leverrier P et al. Dissecting the machinery that introduces disulfide bonds in Pseudomonas aeruginosa. mBio 4(6), (2013).
108. Heras B, Shouldice SR, Totsika M, Scanlon MJ, Schembri MA, Martin JL. DSB proteins and bacterial pathogenicity. Nat. Rev. Micro. 7(3), 215-225 (2009).